Key Highlights
- Exai Bio names Dave Daly as Chief Executive Officer.
- Daly brings over 30 years of cancer diagnostics and leadership experience.
- Exai’s platform uses oncRNAs and AI for superior cancer detection.
- Daly aims to accelerate product development and strategic partnerships.
Source: Business Wire
Notable Quotes
- “Decades spent in the diagnostics industry allowed me to clearly see that Exai’s novel liquid biopsy platform stands out as one that can be both truly high performing and accessible for a broad array of patients.” — Dave Daly, Chief Executive Officer at Exai Bio
- “Since its founding, Exai has amassed the largest oncRNA dataset and honed its proprietary generative AI models to deliver unprecedented sensitivity across the major cancer types.” — Michael Pellini, General Partner at Section 32 and Board member at Exai Bio
SoHC's Take
The appointment of Dave Daly as CEO of Exai Bio is a strategic move that leverages his extensive background in cancer diagnostics and executive leadership. His previous roles at notable companies like Thrive Earlier Detection and Foundation Medicine underscore his capability to drive innovation and growth. Exai Bio’s unique approach, combining oncRNA technology with generative AI, positions it at the forefront of liquid biopsy advancements. Daly’s leadership is expected to propel the company’s product development and partnership initiatives, enhancing its potential to deliver high-performance, accessible cancer diagnostics to a broader patient population.
